News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • AEP raised its long-term growth outlook and announced a $100B five-year capital plan tied to contracted Texas load.
  • Market trade pitched: long AEP toward $150, with a ~3% dividend and a stop below $122.
  • AEP's planned buildout raises utility capex expectations and supports related equipment and construction firms.
  • Ichor shares are down more than 25% since summer while revenue growth and Q3 guidance remain intact.
  • The selloff in Ichor looks driven by multiple compression and headline risk, creating a potential defined long entry.
  • Traders proposing Ichor long outline entry, stop, and targets around the next earnings catalyst for asymmetric reward-risk.

Latest Articles

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Limited announced the launch of two physician-partnered chrono-nutrition nutraceutical formulations in Taiwan, developed collaboratively with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute. This initiative marks the company's first step in building a repeatable physician-partnership ecosystem aimed at meeti…

Abundia Global Impact Group Provides Business Update Highlighting Continued Execution of Commercialization Strategy

Abundia Global Impact Group Provides Business Update Highlighting Continued Execution of Commercialization Strategy

Abundia Global Impact Group, Inc. announced significant progress in its commercialization strategy during Q2 2026, including the acquisition and integration of RPD Technologies, expansion of its Cedar Port facility, and securing strategic partnerships such as with Topsoe and Burns & McDonnell. The company increased revenue to $2 million for the qua…

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Mereo BioPharma has partnered with Sentynl Therapeutics to grant Sentynl exclusive US commercialization and global manufacturing rights for alvelestat, an investigational oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). The agreement includes upfront payments, milestone potential up to $435 million, and royalties…

CN Reports a Record 2025-26 Crop Year

CN Reports a Record 2025-26 Crop Year

CN announced a record movement of over 33.8 million metric tonnes of grain from Western Canada during the 2025-26 crop year, surpassing the previous year's record. This growth was driven by strong customer demand and operational efficiency. CN also released its 2026-27 Grain Plan aimed at further supporting the grain supply chain in the upcoming ha…

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company listed on Nasdaq, announced receipt of an additional A$5.1 million R&D tax incentive refund from the Australian Government. This completes over A$11.2 million received in 2026 as non-dilutive capital, enhancing the company's cash position and debt-free balance sheet to support adv…

Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders

Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders

Anavex Life Sciences Corp. filed its definitive proxy materials for the upcoming 2026 Annual Meeting, urging stockholders to vote for its six highly qualified, independent director nominees. The company highlights recent leadership changes to stabilize operations and advance its CNS-focused drug development programs, particularly the oral blarcames…

GameStop’s Turnaround Looks Investable — Upgrade to Buy

GameStop’s Turnaround Looks Investable — Upgrade to Buy

GameStop has been written off as a meme relic and a retail dinosaur. The closer look shows a real cash cushion, healthy free cash flow, and valuation metrics that leave upside if execution holds. We upgrade to Buy and lay out an actionable trade with defined entry, stop and target for a mid-term swing.

Seagate: Buy the AI Capacity Story Before It Becomes Consensus

Seagate: Buy the AI Capacity Story Before It Becomes Consensus

Seagate sits squarely in the path of AI-driven storage demand. The company just delivered a dramatic revenue pop tied to AI infrastructure and is trading at premium multiples, but strong free cash flow, exceptional returns on assets and a dominant position in high-capacity HDDs make a tactical long look appropriate. This trade idea outlines entry, …

Intel Pullback: Tactical Long After a Sharp Reset

Intel Pullback: Tactical Long After a Sharp Reset

Intel’s stock has pulled back from recent highs and now trades below its 50-day weight but above short-term moving averages. Fundamentals show meaningful top-line traction in foundry and data-center AI, improving unit economics, and $2.8B in trailing free cash flow. Valuation still prices in performance gains; this trade buys the risk/reward as Int…

First Advantage Shares Drop as Sponsor Launches Large Secondary Sale

First Advantage Shares Drop as Sponsor Launches Large Secondary Sale

First Advantage shares fell sharply in pre-market trading after Silver Lake Group, the private equity sponsor, announced an underwritten secondary sale of 12.5 million First Advantage common shares. An additional SEC registration covering up to 87.45 million shares held by selling stockholders expands the potential supply overhang. The company itse…

First Advantage Shares Drop After Major Shareholder Launches Secondary Sale

First Advantage Shares Drop After Major Shareholder Launches Secondary Sale

First Advantage shares slid about 8% Tuesday morning following an announcement that certain Silver Lake funds and affiliates intend to sell 12,500,000 shares of common stock in an underwritten secondary offering. The company itself will not be selling shares or receiving proceeds. Bloomberg reported the sale range at $22.20 to $23.59, while shares …

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

Bicara Therapeutics reported Q2 2026 financials and strategic leadership updates. Ryan Cohlhepp will become CEO in January 2027, succeeding Claire Mazumdar who will transition to Vice Chair and Strategic Advisor. The company is progressing enrollment for the pivotal FORTIFI-HN01 trial of its lead drug, ficerafusp alfa, targeting HPV-negative head a…

Stardust Power Appoints Ray Rivers to Board of Directors

Stardust Power Appoints Ray Rivers to Board of Directors

Stardust Power Inc., a U.S.-based developer of battery-grade lithium carbonate refineries, appointed V. Ray Rivers to its Board of Directors. Rivers brings over 30 years of capital markets and financial services expertise, taking roles on the Audit and Compensation Committees. This strategic appointment aims to deepen the Board's financial expertis…

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Eikon Therapeutics announced the selection of a 0.60 mg/m² dose for EIK1001 in the adaptive Phase 2/3 TeLuRide-006 trial for advanced melanoma, following a recommendation from an independent Data Monitoring Committee. EIK1001 is an investigational dual TLR7/8 agonist designed to stimulate innate and adaptive immunity, potentially enhancing response…

ZenaTech’s ZenaDrone Begins In-House PCB Flight Testing, Advancing Vertical Integration Strategy Toward NDAA-Compliant Blue UAS Certification and Expanded Defense Opportunities

ZenaTech’s ZenaDrone Begins In-House PCB Flight Testing, Advancing Vertical Integration Strategy Toward NDAA-Compliant Blue UAS Certification and Expanded Defense Opportunities

ZenaTech, Inc., a Nasdaq-listed AI drone technology company, announced that its subsidiary ZenaDrone has begun flight testing custom-designed PCBs made in-house at its Taiwan subsidiary and integrated at its UAE facility. This advances their vertical integration strategy aimed at achieving NDAA-compliant Blue UAS certification, facilitating access …